FCGR3A and acute myeloid leukemia: The CD16/IL-15/CD33 TriKE not only was able to enhance NK function against CD33+ cell lines and AML blasts, but also to expand and sustain human NK cells in vivo, reducing tumor burden in a xenograft model (166).